CRISPR Therapeutics AG (MEX:CRSP) ROCE % : -28.05% (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is CRISPR Therapeutics AG ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. CRISPR Therapeutics AG's annualized ROCE % for the quarter that ended in Jun. 2024 was -28.05%.

CRISPR Therapeutics AG ROCE % Historical Data

The historical data trend for CRISPR Therapeutics AG's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CRISPR Therapeutics AG ROCE % Chart

CRISPR Therapeutics AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

6.27

-26.34

17.32

-27.52

-9.76

CRISPR Therapeutics AG Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
ROCE %	Get a 7-Day Free Trial															-17.84	-26.43	13.42	-25.05	-28.05

CRISPR Therapeutics AG ROCE % Calculation

CRISPR Therapeutics AG's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-3777.415	/	( ( (43730.639 - 2361.102)	+	(37845.291 - 1846.645) )	/ 2 )
	=	-3777.415	/	( (41369.537	+	35998.646)	/ 2 )
	=	-3777.415	/	38684.0915
	=	-9.76 %

CRISPR Therapeutics AG's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Mar. 2024 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Mar. 2024 )		(Q: Jun. 2024 )
	=	-11084.396	/	( ( (40478.548 - 1974.788)	+	(42866.348 - 2341.731) )	/ 2 )
	=	-11084.396	/	( ( 38503.76	+	40524.617 )	/ 2 )
	=	-11084.396	/	39514.1885
	=	-28.05 %

(1) Note: The EBIT data used here is four times the quarterly (Jun. 2024) EBIT data.

CRISPR Therapeutics AG (MEX:CRSP) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

CRISPR Therapeutics AG ROCE % Related Terms

Thank you for viewing the detailed overview of CRISPR Therapeutics AG's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

CRISPR Therapeutics AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CRISPR Therapeutics AG (MEX:CRSP) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

CRSP:USA 0VRQ:UK

Address

Baarerstrasse 14, Zug, CHE, CH-6300

Website

https://www.crisprtx.com

CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, exa-cel, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.